coiaward2010

Webinar: GENERIC TKIs IN CML

The Glivec patent expires in most countries latest on 21 Dec 2016.

The CML Advocates Network has been following the situation of TKI generics closely for 3 years, and has now provided a webinar which summarizes the current status.

This webinar answers some important questions, such as:

  • What are generics, and do they differentiate from innovator products?
  • Which generics of CML Tyrosine Kinase Inhibitors exist?
  • What do we know about efficacy and safety?
  • What information on CML generics is available to patients?
  • What has the patient advocacy community done so far?
  • What can patients and patient advocacy groups do about CML generics?

More can be found on our CML Advocates Network Knowledge Base on CML Generics at http://www.cmladvocates.net/generics.

If you want access to the slides, please contact Jan Geissler at .

Webstream via AuthorStream (allows to skip slides)

 

 

 

 

 

 

 

 

webinar

Subcategories

Please donate!

Please donate!

LogIn

Tweet Feed

cmlnet
Call for Abstracts: CML Advocacy Best Practice presentations at CML Horizons 2017.Submit your abstract here… twitter.com/i/web/status/8…

Wednesday, 22 March 2017

VJHemOnc
VIDEO: @jangeissler on new European programs and initiatives relevant to #hematology: ow.ly/HciI309ZN0T @cmlnet #bloodcancer

Retweeted Friday, 17 March 2017

patientpowereu
Factors influencing adherence in CML and ways to improvement ow.ly/FjgD309ZP9H > @cmlnet #CML

Retweeted Friday, 17 March 2017